Bone Marrow-Derived Mesenchymal Stem Cells Induce Both Polyclonal Expansion and Differentiation of B Cells Isolated from Healthy Donors and Systemic Lupus Erythematosus Patients
Article first published online: 15 NOV 2007
Copyright © 2008 AlphaMed Press
Volume 26, Issue 2, pages 562–569, February 2008
How to Cite
Traggiai, E., Volpi, S., Schena, F., Gattorno, M., Ferlito, F., Moretta, L. and Martini, A. (2008), Bone Marrow-Derived Mesenchymal Stem Cells Induce Both Polyclonal Expansion and Differentiation of B Cells Isolated from Healthy Donors and Systemic Lupus Erythematosus Patients. STEM CELLS, 26: 562–569. doi: 10.1634/stemcells.2007-0528
- Issue published online: 2 JAN 2009
- Article first published online: 15 NOV 2007
- Manuscript Accepted: 5 NOV 2007
- Manuscript Received: 4 JUL 2007
- Mesenchymal stem cells;
- B-cell subsets;
- Systemic autoimmunity;
- Polyclonal stimulation
Human bone marrow multipotent mesenchymal stromal cells are progenitor cells that can be expanded in vitro and differentiate into various cells of mesodermal origin. They contribute to the bone marrow reticular niche, where mature B cells and long-lived plasma cells are maintained. Multipotent mesenchymal stromal cells were recently shown to modulate T- and B-cell proliferation and differentiation, dendritic cell maturation, and natural killer activity. These immunoregulatory properties encouraged a possible use of these cells to modulate autoimmune responses in humans. We studied the influence of bone marrow mesenchymal stem cells on highly purified B-cell subsets isolated from healthy donors and total B cells from pediatric systemic lupus erythematosus patients. Bone marrow mesenchymal stem cells promoted proliferation and differentiation into immunoglobulin-secreting cells of transitional and naïve B cells stimulated with an agonist of Toll-like receptor 9, in the absence of B cell receptor triggering. They strongly enhanced proliferation and differentiation into plasma cells of memory B-cell populations. A similar effect was observed in response to polyclonal stimulation of B cells isolated from pediatric patients with systemic lupus erythematosus. This study casts important questions on bone marrow mesenchymal stem cells as a therapeutic tool in autoimmune diseases in which B-cell activation is crucially implicated in the pathogenesis of the disease.
Disclosure of potential conflicts of interest is found at the end of this article.